Cargando…
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment
Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical tr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725068/ https://www.ncbi.nlm.nih.gov/pubmed/29246026 http://dx.doi.org/10.18632/oncotarget.19852 |
_version_ | 1783285469679714304 |
---|---|
author | Raimondi, Lavinia De Luca, Angela Costa, Viviana Amodio, Nicola Carina, Valeria Bellavia, Daniele Tassone, Pierfrancesco Pagani, Stefania Fini, Milena Alessandro, Riccardo Giavaresi, Gianluca |
author_facet | Raimondi, Lavinia De Luca, Angela Costa, Viviana Amodio, Nicola Carina, Valeria Bellavia, Daniele Tassone, Pierfrancesco Pagani, Stefania Fini, Milena Alessandro, Riccardo Giavaresi, Gianluca |
author_sort | Raimondi, Lavinia |
collection | PubMed |
description | Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20–30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of non-invasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice. |
format | Online Article Text |
id | pubmed-5725068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57250682017-12-14 Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment Raimondi, Lavinia De Luca, Angela Costa, Viviana Amodio, Nicola Carina, Valeria Bellavia, Daniele Tassone, Pierfrancesco Pagani, Stefania Fini, Milena Alessandro, Riccardo Giavaresi, Gianluca Oncotarget Review Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20–30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of non-invasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice. Impact Journals LLC 2017-08-03 /pmc/articles/PMC5725068/ /pubmed/29246026 http://dx.doi.org/10.18632/oncotarget.19852 Text en Copyright: © 2017 Raimondi et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Raimondi, Lavinia De Luca, Angela Costa, Viviana Amodio, Nicola Carina, Valeria Bellavia, Daniele Tassone, Pierfrancesco Pagani, Stefania Fini, Milena Alessandro, Riccardo Giavaresi, Gianluca Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
title | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
title_full | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
title_fullStr | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
title_full_unstemmed | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
title_short | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
title_sort | circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725068/ https://www.ncbi.nlm.nih.gov/pubmed/29246026 http://dx.doi.org/10.18632/oncotarget.19852 |
work_keys_str_mv | AT raimondilavinia circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT delucaangela circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT costaviviana circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT amodionicola circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT carinavaleria circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT bellaviadaniele circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT tassonepierfrancesco circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT paganistefania circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT finimilena circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT alessandroriccardo circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment AT giavaresigianluca circulatingbiomarkersinosteosarcomanewtranslationaltoolsfordiagnosisandtreatment |